https://orcid.org/0000-0001-8737-9110
References
- WHO Regional Office for Europe/European Centre for Disease Prevention and Control. Antimicrobial resistance surveillance in Europe 2022 – 2020 data. Copenhagen: WHO Regional Office for Europe; 2022. https://www.ecdc.europa.eu/en/publications-data/antimicrobial-resistance-surveillance-europe-2022-2020-data.
- Candel FJ, Matesanz David M, Barberán J. New perspectives for reassessing fosfomycin: applicability in current clinical practice. Rev Esp Quimioter. 2019;32(Suppl 1):1–7.
- Falagas ME, Vouloumanou EK, Samonis G, et al. Fosfomycin. Clin Microbiol Rev. 2016;29(2):321–347.
- Dijkmans AC, Zacarías NVO, Burggraaf J, et al. Fosfomycin: pharmacological, clinical and future perspectives. Antibiotics (Basel). 2017;6(4):24.
- Agyeman AA, Bergen PJ, Rao GG, et al. A systematic review and meta-analysis of treatment outcomes following antibiotic therapy among patients with carbapenem-resistant Klebsiella pneumoniae infections. Int J Antimicrob Agents. 2020;55(1):105833.
- Michalopoulos A, Virtzili S, Rafailidis P, et al. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin Microbiol Infect. 2010;16(2):184–186.
- Pontikis K, Karaiskos I, Bastani S, et al. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing gram-negative bacteria. Int J Antimicrob Agents. 2014;43(1):52–59.
- Liao Y, Hu GH, Xu YF, et al. Retrospective analysis of fosfomycin combinational therapy for sepsis caused by carbapenem-resistant Klebsiella pneumoniae. Exp Ther Med. 2017;13(3):1003–1010.
- Abdallah TAK, Elajez R, Ibrahim TB, et al. Efficacy and safety of intravenous fosfomycin for the treatment of difficult-to-treat gram-negative bacterial infections. J Infect Public Health. 2021;14(11):1620–1622.
- Reffert JL, Smith WJ. Fosfomycin for the treatment of resistant gram-negative bacterial infections. Insights from the society of infectious diseases pharmacists. Pharmacotherapy. 2014;34(8):845–857.
- Sojo-Dorado J, López-Hernández I, Rosso-Fernandez C, REIPI-GEIRAS-FOREST group, et al. Effectiveness of fosfomycin for the treatment of multidrug-resistant Escherichia coli bacteremic urinary tract infections: a randomized clinical trial. JAMA Netw Open. 2022;5(1):e2137277.
- Shi Y, Hu J, Liu P, et al. Ceftazidime-avibactam-based versus tigecycline-based regimen for the treatment of carbapenem-resistant Klebsiella pneumoniae-induced pneumonia in critically ill patients. Infect Dis Ther. 2021;10(4):2721–2734.
- Abdelsalam MFA, Abdalla MS, El-Abhar HSE. Prospective, comparative clinical study between high-dose colistin monotherapy and colistin-meropenem combination therapy for treatment of hospital-acquired pneumonia and ventilator-associated pneumonia caused by multidrug-resistant Klebsiella pneumoniae. J Glob Antimicrob Resist. 2018;15:127–135.
- Xu L, Sun X, Ma X. Systematic review and meta-analysis of mortality of patients infected with carbapenem-resistant Klebsiella pneumoniae. Ann Clin Microbiol Antimicrob. 2017;16(1):18.
- Lou T, Du X, Zhang P, et al. Risk factors for infection and mortality caused by carbapenem-resistant Klebsiella pneumoniae: a large multicentre case-control and cohort study. J Infect. 2022;84(5):637–647.
- Bassetti M, Graziano E, Berruti M, et al. The role of fosfomycin for multidrug-resistant gram-negative infections. Curr Opin Infect Dis. 2019;32(6):617–625.
- Trinh TD, Smith JR, Rybak MJ. Parenteral fosfomycin for the treatment of multidrug resistant bacterial infections: the rise of the epoxide. Pharmacotherapy. 2019;39(11):1077–1094.
- Florent A, Chichmanian RM, Cua E, et al. Adverse events associated with intravenous fosfomycin. Int J Antimicrob Agents. 2011;37(1):82–83.
- Putensen C, Ellger B, Sakka SG, et al. Current clinical use of intravenous fosfomycin in ICU patients in two European countries. Infection. 2019;47(5):827–836.
- Scavone C, Mascolo A, Bernardi FF, et al. Hypernatremia during intravenous treatment with fosfomycin: a retrospective medical record review study and an analysis of spontaneous reports in the EudraVigilance database. Front Pharmacol. 2022;13:844122.